MICROGEN
BIOPRODUCTS

Microgen Bioproducts® SARS-CoV-2 IgG EIA



For the qualitative detection of specific IgG antibodies against SARS-CoV-2

enquiries.microgen@novacyt.com | +44 (0) 1276 600 081 | www.microgenbioproducts.com

twitter.com/MicrogenBioProd linkedin.com/company/microgen-bioproducts-ltd

What is the test?

The Microgen Bioproducts® SARS-CoV-2 IgG EIA introduces a highly sensitive & specific assay for the qualitative detection of IgG antibodies, usually formed two weeks after initial infection[6]. The test is intended for the screening of patients previously infected, to either; confirm the infection, monitor the course of disease or to draw epidemiological conclusions[3].

Each kit contains 480 reactions (5x96 well plates) and includes all additional reagents required to perform each test – alongside positive/negative controls; sample types include human serum and plasma.

Background

SARS-CoV-2 belongs the *Coronaviridae* family of viruses and is closely related to the SARS virus of 2002/2003[1]. It was first identified in humans at the end of 2019 (Wuhan, China) and is transmissible from person to person[2]. Primary transmission occurs through the aspiration of infected droplets, infections via aerosols and smear are also suggested[2,4].

Viral incubation is typically three to seven days[2] and can reside asymptomatically within infected individuals, or only presenting mild symptoms. These often include a dry cough & fever[3,4], however, in more severe clinical manifestations an infected individual can develop a severe pneumonia, which can lead to death.

Ordering Information	Product Information
Product Code: MBCOV2CE	**Specificity:** 99.4%
Pack Size: 480 tests	**Sensitivity:** 100%

KEY FEATURES

- Accurate detection of SARS-CoV-2 IgG antibodies
- High sensitivity and specificity
- < 1 hour 30 minutes incubation time
- No cross-reactivity with common viral pathogens
- No additional reagents required

Applications

The test supports diagnosis of a SARS-CoV-2 infection and is a supplement to the pathogen's initial detection, typically conducted via RT-PCR[5]. Additionally, serological testing can be used by health authorities to investigate the immune status of a population, identify viral reservoir hosts, and evaluate vaccine trials.

References:

1) Gorbalenya et al., The species Severe acute respiratory syndrome-related coronavirus: classifying 2019- nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020;5(4):536–44.

2) Gralinski & Menachery. Return of the coronavirus: 2019-nCoV. Viruses. 2020;12(2):1–8.

3) Udugama et al., Diagnosing COVID-19: The Disease and Tools for Detection. ACS Nano. 2020;14(4):3822–35.

4) Xiao et al., Evolving status of the 2019 novel coronavirus infection: Proposal of conventional serologic assays for disease diagnosis and infection monitoring. J Med Virol. 2020;92(5):464–7.

5) WHO. Laboratory testing for coronavirus disease 2019 (COVID-19) in suspected human cases. Interim Guide [Internet]. 2020:1–7. Available from: https://www.who.int/publications-detail/laboratory-tes- ting-for-2019-novel-coronavirus-in-suspected-human-cases-20200117

6) Okba et al., Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Corona- virus Disease 2019 Patients. Emerg Infect Dis. 2020;26(7):1478–88.

About Us

Microgen Bioproducts® is a subsidiary of the Novacyt Group alongside Primerdesign™ and Lab 21 Healthcare. With over 20 years of experience in the development, manufacture and distribution of high-quality diagnostic products for clinical and food laboratories.

NOVACYT GROUP

Get in Touch

enquiries.microgen@novacyt.com
+44 (0) 1276 600 081
www.microgenbioproducts.com